Table 2. Associations between the expression of SFRP4 and clinicopathological characteristics at baseline.
| Characteristics | Positive expression of SFRP4 (n=25) | Negative expression of SFRP4 (n=175) | P value |
|---|---|---|---|
| Age at onset, mean (SD) (median), y | 56.0 (10.1) (55.0) | 61.0 (10.1) (61.0) | 0.021* |
| Male, n (%) | 13 (12.0%) | 95 (88.0%) | 0.830 |
| Female, n (%) | 12 (13.0%) | 80 (87.0%) | 0.018* |
| Tumor size, mean (median), cm | 3.1 (2.8) | 3.5 (3.2) | |
| Regional lymph node metastases, n (%) | 5 (25.0%) | 76 (52.1%) | 0.023* |
| Location, n (%) | 0.359 | ||
| Head | 19 (76.0%) | 6 (24.0%) | |
| Distal | 117 (66.9%) | 58 (33.1%) | |
| Extrapancreatic organ invasion, n (%) | 22 (88.0%) | 166 (94.5%) | 0.177 |
| Neural invasion, n (%) | 16 (64.0%) | 134 (76.6%) | 0.175 |
| Vascular invasion, n (%) | 4 (16.0%) | 19 (10.9%) | 0.451 |
| Tumor microthrombus, n (%) | 3 (12.0%) | 17 (9.7%) | 0.722 |
| Necrosis, n (%) | 2 (8.0%) | 11 (6.3%) | 0.745 |
| Differentiation, n (%) | 0.022* | ||
| Grade 1 | 5 (29.4%) | 12 (70.6%) | |
| Grade 2 | 8 (10.3%) | 70 (89.7%) | |
| Grade 2-3 | 8 (20.5%) | 31 (79.5%) | |
| Grade 3 | 4 (6.1%) | 62 (93.9%) |
*P < 0.05